{"id":"anti-il23","safety":{"commonSideEffects":[{"rate":"10%","effect":"Headache"},{"rate":"8%","effect":"Nausea"},{"rate":"5%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IL-23 is a pro-inflammatory cytokine involved in the pathogenesis of various autoimmune and inflammatory diseases. Inhibiting IL-23 has been shown to reduce inflammation and modulate the immune response.","oneSentence":"IL-23 inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:03.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT06598943","phase":"PHASE2","title":"A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-10","conditions":"Ulcerative Colitis, Ulcerative Colitis Chronic","enrollment":140},{"nctId":"NCT07245394","phase":"","title":"Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)","status":"RECRUITING","sponsor":"TIDHI Innovation Inc.","startDate":"2026-01-29","conditions":"Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)","enrollment":200},{"nctId":"NCT04572815","phase":"PHASE2","title":"Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-14","conditions":"Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm","enrollment":116},{"nctId":"NCT05283135","phase":"PHASE2","title":"High Dose Risankizumab for Psoriasis","status":"COMPLETED","sponsor":"Oregon Medical Research Center","startDate":"2022-03-01","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT06274554","phase":"PHASE3","title":"Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-10-04","conditions":"Crohn's Disease, Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT07198113","phase":"","title":"COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-11-01","conditions":"Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease","enrollment":1100},{"nctId":"NCT02648581","phase":"PHASE2","title":"Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-14","conditions":"Behçet Disease","enrollment":16},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03358693","phase":"","title":"Molecular Signatures in Inflammatory Skin Disease","status":"RECRUITING","sponsor":"Prof. Dr. Stephan Weidinger","startDate":"2017-01-20","conditions":"Atopic Dermatitis, Psoriasis","enrollment":300},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT06399432","phase":"NA","title":"Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2022-10-18","conditions":"Psoriasis","enrollment":36},{"nctId":"NCT05111210","phase":"","title":"Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2021-12-14","conditions":"Psoriasis","enrollment":90},{"nctId":"NCT05054361","phase":"","title":"Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2022-01-01","conditions":"Type1diabetes","enrollment":180},{"nctId":"NCT06089590","phase":"","title":"Ibd CAncer and seRious Infections in France (I-CARE 2)","status":"RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2024-01-25","conditions":"IBD, Ulcerative Colitis, Crohn Disease","enrollment":6000},{"nctId":"NCT04505410","phase":"PHASE3","title":"Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Miami","startDate":"2020-09-18","conditions":"Ulcerative Colitis","enrollment":32},{"nctId":"NCT06844799","phase":"PHASE3","title":"A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-06-10","conditions":"Moderate-to-severe Plaque Psoriasis","enrollment":720},{"nctId":"NCT06792487","phase":"","title":"Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-09-04","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT05290363","phase":"NA","title":"The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2022-10-06","conditions":"Spondyloarthritis","enrollment":90},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT04971200","phase":"EARLY_PHASE1","title":"Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo","status":"COMPLETED","sponsor":"Premier Specialists, Australia","startDate":"2021-09-16","conditions":"Skin and Connective Tissue Diseases, Skin Diseases, Pigmentation Disorder","enrollment":12},{"nctId":"NCT04736966","phase":"PHASE1","title":"Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2021-03-03","conditions":"Alcoholic Liver Disease","enrollment":13},{"nctId":"NCT01947933","phase":"PHASE1","title":"A Safety Study of Mirikizumab (LY3074828)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-10","conditions":"Psoriasis","enrollment":45},{"nctId":"NCT04458311","phase":"PHASE1, PHASE2","title":"Abiraterone Acetate in Combination With Tildrakizumab","status":"TERMINATED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-01","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":13},{"nctId":"NCT06055699","phase":"","title":"Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03-01","conditions":"Psoriasis, Microbial Colonization","enrollment":50},{"nctId":"NCT05957120","phase":"","title":"Subclinical Impairment of Cardiovascular System in Patients With Psoriasis","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2022-01-03","conditions":"Psoriasis, Inflammation, Endothelial Dysfunction","enrollment":100},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT05499416","phase":"PHASE4","title":"Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis","status":"WITHDRAWN","sponsor":"Innovaderm Research Inc.","startDate":"2023-01","conditions":"Psoriasis Vulgaris, Active Psoriatic Arthritis","enrollment":""},{"nctId":"NCT03690544","phase":"PHASE4","title":"Apremilast for RAS","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-10-12","conditions":"Recurrent Aphthous Stomatitis","enrollment":15},{"nctId":"NCT02574637","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2016-01-05","conditions":"Crohn's Disease","enrollment":29},{"nctId":"NCT02955147","phase":"PHASE1, PHASE2","title":"Ustekinumab for the Treatment of Giant Cell Arteritis","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2016-12-01","conditions":"Giant Cell Arteritis, Temporal Arteritis, Horton's Disease","enrollment":13},{"nctId":"NCT04084665","phase":"EARLY_PHASE1","title":"Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.","status":"WITHDRAWN","sponsor":"Rockefeller University","startDate":"2020-06-01","conditions":"Hidradenitis Suppurativa","enrollment":""},{"nctId":"NCT03255382","phase":"PHASE3","title":"A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-08-22","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT01999868","phase":"PHASE2","title":"Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-03-19","conditions":"Psoriasis","enrollment":108},{"nctId":"NCT02031276","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-02","conditions":"Crohn Disease","enrollment":121},{"nctId":"NCT03565042","phase":"","title":"Mechanism of Action of Ustekinumab in Psoriatic Arthritis","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2015-12-08","conditions":"Arthritis, Psoriatic","enrollment":16},{"nctId":"NCT02883894","phase":"","title":"Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2009-11","conditions":"Bullous Pemphigoid","enrollment":120},{"nctId":"NCT01845987","phase":"PHASE2","title":"A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2013-06","conditions":"Palmoplantaris Pustulosis","enrollment":49},{"nctId":"NCT00267956","phase":"PHASE2","title":"An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Psoriatic Arthritis","enrollment":146},{"nctId":"NCT00771667","phase":"PHASE2","title":"A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2008-12","conditions":"Crohn's Disease","enrollment":526}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":92,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Anti-IL23","genericName":"Anti-IL23","companyName":"Prof. Dr. Stephan Weidinger","companyId":"prof-dr-stephan-weidinger","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IL-23 inhibitor Used for Psoriasis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}